AtheroGenics, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant rejection, rheumatoid arthritis and asthma in the United States. It owns a vascular protectant or v-protectant technology platform to discover drugs. The company’s products primarily include AGI-1067, a Phase III clinical trial product, which would be used for the treatment of coronary heart disease atherosclerosis; and AGI-1096 a Phase I clinical trial antioxidant and selective anti-inflammatory agent, for the treatment of transplant rejection. The company has collaboration agreement with...